DelveInsight’s, “Advanced Ovarian Cancer Pipeline Insight 2024” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Advanced Ovarian Cancer pipeline landscape. It covers the Advanced Ovarian Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Advanced Ovarian Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Advanced Ovarian Cancer Research. Learn more about our innovative pipeline today! @ Advanced Ovarian Cancer Pipeline Outlook
Key Takeaways from the Advanced Ovarian Cancer Pipeline Report
Stay informed about the cutting-edge advancements in Advanced Ovarian Cancer Treatments. Download for updates and be a part of the revolution in cancer care @ Advanced Ovarian Cancer Clinical Trials Assessment
Advanced Ovarian Cancer Emerging Drugs Profile
Oregovomab is a murine IgG against CA 125. Indirect immunization with oregovomab interacts with immune modulating properties of infused paclitaxel and carboplatin resulting in synergistic clinical benefit as observed in this phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab demonstrated a highly clinically significant outcome for both progression-free and overall survival favoring the addition of oregovomab to a standard of care chemotherapy combination of carboplatin and paclitaxel. The risk of progression and of death was reduced by more than 50% when compared to placebo, and safety data showed that oregovomab did not add incremental toxicity to the chemotherapy regimen.
Stenoparib (2X-121) is a unique, small molecule dual targeted inhibitor of Poly ADP-Ribose Polymerases (PARP 1 and 2) and telomerase maintenance enzymes (Tankyrase 1 and 2). Allarity exclusively in-licensed it (globally) from Eisai. It is currently in Phase 2 testing for ovarian cancer with patients selected by the Stenoparib DRP. The Stenoparib DRP® is validated for ovarian cancer. It is currently being evaluated for the treatment of advanced ovarian cancer in a Phase 2 clinical trial at the Dana-Farber Cancer Institute using the Stenoparib DRP® companion diagnostic to guide patient enrollment and improve therapeutic outcome.
DP-303c is under development for the treatment of HER2 low expressing solid tumors, gastric cancer including gastroesophageal junction, breast cancer, adenocarcinoma of the gastroesophageal junction, epithelial ovarian cancer, fallopian tube cancer and primary peritoneal cancer. The drug candidate is an antibody drug conjugate that is administered by intravenous route. It acts by targeting human epidermal growth factor receptor 2 (HER2).
Learn more about Advanced Ovarian Cancer Drugs opportunities in our groundbreaking Advanced Ovarian Cancer Research and development projects @ Advanced Ovarian Cancer Unmet Needs
Advanced ovarian cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
Advanced Ovarian Cancer Products have been categorized under various Molecule types such as
Discover the latest advancements in Advanced Ovarian Cancer Treatment by visiting our website. Stay informed about how we’re transforming the future of Oncology @ Advanced Ovarian Cancer Market Drivers and Barriers, and Future Perspectives
Advanced Ovarian Cancer Companies and Therapies
Scope of the Advanced Ovarian Cancer Pipeline Report
For a detailed overview of our latest research findings and future plans, read the full details of Advanced Ovarian Cancer Pipeline on our website @ Advanced Ovarian Cancer Drugs and Companies
Table of Content
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/